O63 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among SELECTIONLT...
O63 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitis
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
IntroductionFilgotinib (FIL) is an oral, JAK1 preferential inhibitor approved for the treatment of UC. FIL 200 mg (FIL200) was effective in inducing and maintaining clinical remission vs placebo (PBO) and well tolerated in the phase 2b/3 SELECTION trial (NCT02914522). The efficacy and safety of continued FIL200 are being assessed in the continuing...
Alternative Titles
Full title
O63 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2828908480
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2828908480
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2023-BSG.62
